Patents Assigned to ARAVAX PTY LTD
-
Publication number: 20240415955Abstract: The present invention relates generally to an immunotherapeutic composition. More particularly, the present invention relates to an immunotherapeutic composition which interacts immunologically with T lymphocytes in subjects having peanut allergy or allergy to other tree nuts. This composition is preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 and/or Ara h 2 allergens. The composition of the present invention is useful in the therapeutic or prophylactic treatment of conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to peanut, Ara h 1 and/or Ara h 2 or derivative or homologue thereof.Type: ApplicationFiled: April 22, 2024Publication date: December 19, 2024Applicant: ARAVAX PTY LTD.Inventors: Robyn Elizabeth O'Hehir, Sara Rachel Prickett, Jennifer May Rolland
-
Publication number: 20240350599Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.Type: ApplicationFiled: March 26, 2024Publication date: October 24, 2024Applicant: ARAVAX PTY LTDInventors: ROBYN O'HEHIR, JENNIFER ROLLAND, SARA PRICKETT
-
Publication number: 20240350600Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.Type: ApplicationFiled: June 26, 2024Publication date: October 24, 2024Applicant: ARAVAX PTY LTDInventors: ROBYN O'HEHIR, JENNIFER ROLLAND, SARA PRICKETT
-
Publication number: 20240252607Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.Type: ApplicationFiled: December 22, 2023Publication date: August 1, 2024Applicant: ARAVAX PTY LTDInventors: ROBYN O'HEHIR, JENNIFER ROLLAND, SARA PRICKETT
-
Patent number: 11980658Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.Type: GrantFiled: July 13, 2021Date of Patent: May 14, 2024Assignee: ARAVAX PTY LTDInventors: Robyn O'Hehir, Jennifer Rolland, Sara Prickett
-
Patent number: 11266737Abstract: The present invention relates generally to an immunotherapeutic composition. More particularly, the present invention relates to an immunotherapeutic composition which interacts immunologically with T lymphocytes in subjects having peanut allergy or allergy to other tree nuts. This composition is preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 and/or Ara h 2 allergens. The composition of the present invention is useful in the therapeutic or prophylactic treatment of conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to peanut, Ara h 1 and/or Ara h 2 or derivative or homologue thereof.Type: GrantFiled: September 25, 2014Date of Patent: March 8, 2022Assignee: ARAVAX PTY LTDInventors: Robyn Elizabeth O'Hehir, Sara Rachel Prickett, Jennifer May Rolland
-
Patent number: 11096994Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.Type: GrantFiled: October 30, 2013Date of Patent: August 24, 2021Assignee: ARAVAX PTY LTDInventors: Robyn O'Hehir, Jennifer Rolland, Sara Prickett